Skip to Main Content

Paper Details

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.
Front Med (Lausanne)
2
2022
cancer, entrectinib, larotrectinib, pembrolizumab
Author NameAffiliation
Emile E VoestThe Netherlands Cancer Institute
Emile E VoestOncode Institute
Anthonius de Boer
Anthonius de BoerUtrecht Institute for Pharmaceutical Sciences, Utrecht University
  • 1 - 4

Datasets

Release 1.2